Plant-produced Recombinant Influenza A Vaccines Based on the M2e Peptide

Title:Plant-produced Recombinant Influenza A Vaccines Based on the M2e Peptide

Volume: 24 Issue: 12

Author(s): Eugenia S. Mardanova and Nikolai V. Ravin*

Affiliation:

• Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, 119071 Moscow,Russian Federation

Keywords: Plant expression system, influenza, vaccine, M2 protein, virus-like particle, plant virus.

Abstract: Background: Influenza is a widely distributed infection that almost annually causes seasonal epidemics. The current egg-based platforms for influenza vaccine production are facing a number of challenges and are failing to satisfy the global demand in the case of pandemics due to the long production time. Recombinant vaccines are an alternative that can be quickly produced in high quantities in standard expression systems.

Methods: Plants may become a promising biofactory for the large-scale production of recombinant proteins due to low cost, scalability, and safety. Plant-based expression systems have been used to produce recombinant vaccines against influenza based on two targets; the major surface antigen hemagglutinin and the transmembrane protein M2.

Results: Different forms of recombinant hemagglutinin were successfully expressed in plants, and some plantproduced vaccines based on hemagglutinin were successfully tested in clinical trials. However, these vaccines remain strain specific, while the highly conserved extracellular domain of the M2 protein (M2e) could be used for the development of a universal influenza vaccine. In this review, the state of the art in developing plant-produced influenza vaccines based on M2e is presented and placed in perspective. A number of strategies to produce M2e in an immunogenic form in plants have been reported, including its presentation on the surface of plant viruses or virus-like particles formed by capsid proteins, linkage to bacterial flagellin, and targeting to protein bodies.

Conclusion: Some M2e-based vaccine candidates were produced at high levels (up to 1 mg/g of fresh plant tissue) and were shown to be capable of stimulating broad-range protective immunity.

Cite this article as:

Mardanova S. Eugenia and Ravin V. Nikolai *, Plant-produced Recombinant Influenza A Vaccines Based on the M2e Peptide, Current Pharmaceutical Design 2018; 24 (12) . https://dx.doi.org/10.2174/1381612824666180309125344